

# NIH GUIDE

---

**For Grants  
and  
Contracts**

---

**NOTICE OF MAILING  
CHANGE**

Check here if you wish to  
discontinue receiving this  
publication

Check here if your address has  
changed and you wish to con-  
tinue receiving this publication.  
Make corrections below and  
mail this page to:

NIH Guide  
Printing & Reproduction Branch  
National Institutes of Health  
Room B4BN08, Building 31  
Bethesda, Maryland 20892

---

**U.S. DEPARTMENT OF HEALTH  
AND HUMAN SERVICES**

OFFICIAL BUSINESS  
Penalty for Private Use, \$300

The NIH Guide announces scientific initiatives and provides policy and administrative information to individuals and organizations who need to be kept informed of opportunities, requirements, and changes in extramural programs administered by the National Institutes of Health.

Vol. 18, No. 40  
November 10, 1989

First Class Mail Postages & Fees Paid PHS/NIH/OD Permit No. G-291
--

NOTICES

NIH/FDA REGIONAL WORKSHOPS - PROTECTION OF HUMAN SUBJECTS ..... 1  
National Institutes of Health  
Food and Drug Administration  
Index: NATIONAL INSTITUTES OF HEALTH  
FOOD AND DRUG ADMINISTRATION

DATED ANNOUNCEMENTS (RFPs AND RFAs)

RESOURCE FOR HUMAN ESOPHAGEAL TISSUE AND CELLS FROM DONORS WITH  
EPIDEMIOLOGICAL PROFILES (RFP) ..... 1  
National Cancer Institute  
Index: CANCER

PRESOLICITATION: MULTI-SITE TRIALS OF BEHAVIORAL STRATEGIES TO  
PREVENT THE FURTHER SPREAD OF HIV INFECTION (RFA) ..... 2  
National Institute of Mental Health  
National Institute on Drug Abuse  
National Institute on Alcohol Abuse and Alcoholism  
Index: MENTAL HEALTH, DRUG ABUSE, ALCOHOL ABUSE, ALCOHOLISM

INTERNATIONAL COLLABORATION IN ACQUIRED IMMUNODEFICIENCY SYNDROME  
RESEARCH (RFA) ..... 3  
National Institute of Allergy and Infectious Diseases  
Index: ALLERGY, INFECTIOUS DISEASES

SPECIALIZED CENTERS OF RESEARCH IN CHRONIC DISEASES OF THE AIRWAYS,  
OCCUPATIONAL AND IMMUNOLOGIC LUNG DISEASES, AND LUNG BIOLOGY AND  
DISEASE IN INFANTS AND CHILDREN (RFA) ..... 4  
National Heart, Lung, and Blood Institute  
Index: HEART, LUNG, BLOOD

ONGOING PROGRAM ANNOUNCEMENTS

PREVENTIVE CARDIOLOGY ACADEMIC AWARD ..... 5  
National Heart, Lung, and Blood Institute  
Index: HEART, LUNG, BLOOD

RESEARCH TRAINING AND CAREER DEVELOPMENT AWARDS IN DIABETES,  
ENDOCRINOLOGY, AND METABOLIC DISEASES ..... 6  
National Institute of Diabetes and Digestive and Kidney Diseases  
Index: DIABETES, DIGESTIVE DISEASES, KIDNEY DISEASES

NOTICES

NIH/FDA REGIONAL WORKSHOPS - PROTECTION OF HUMAN SUBJECTS

P.T. 42; K.W. 0783005

National Institutes of Health  
Food and Drug Administration

The National Institutes of Health (NIH) and the Food and Drug Administration (FDA) are continuing to sponsor a series of workshops on responsibilities of researchers, Institutional Review Boards (IRBs), and institutional officials for the protection of human subjects in biomedical and behavioral research. The workshops are open to everyone with an interest in research. The meetings should be of special interest to those persons currently serving or about to begin serving as a member of an IRB. The current schedule includes:

- o Dates: January 11-12, 1990
- o Location: Houston, Texas
- o Title of Workshop: "1990 IRB Challenges"
- o Contact: Ms. Laurie Flowers  
Conference Coordinator  
Affiliated Systems Corporation  
1200 Post Oak Blvd., Suite 540  
Houston, Texas 77056-3104  
Telephone: (713) 439-0210

NIH/FDA have planned human subjects regional workshops in other parts of the United States. For further information regarding these workshops, contact:

Darlene Marie Ross  
Education Program Coordinator  
Office for Protection from Research Risks  
National Institutes of Health  
Building 31, Room 5B62  
9000 Rockville Pike  
Bethesda, Maryland 20892  
Telephone: (301) 496-8101

DATED ANNOUNCEMENTS (RFPs AND RFAs)

RESOURCE FOR HUMAN ESOPHAGEAL TISSUE AND CELLS FROM DONORS WITH  
EPIDEMIOLOGICAL PROFILES

RFP AVAILABLE: NCI-CP-05605-56

P.T. 34; K.W. 0780005, 0780015, 0780020

National Cancer Institute

The Laboratory of Human Carcinogenesis Branch within the Division of Cancer Etiology, National Cancer Institute (NCI), National Institutes of Health (NIH), is recompeting an ongoing project that currently is being performed by the University of Maryland, Baltimore, Maryland (Contract No. N01-CP-71012).

NCI has a requirement for a contract to collect normal-appearing and neoplastic human esophageal tissue and cells at the time of surgery (cancer and non-cancer donors) and at immediate autopsy (non-cancer donors); and for culturing and storing stocks of epithelial and fibroblastic cells from the esophagus. The offeror must provide approval from the institutional committee for the protection of human subjects; routinely obtain informed donor consent; obtain an epidemiological profile of the donors employing trained interviewers; use proven methods for collecting, culturing, and transporting viable specimens to the NIH within two hours of collection (approximately 40 cases per year); and characterize the functional and pathological status of the tissue by histochemical and immunological methods and by light and electron microscopy.

It is anticipated that one cost-reimbursement type contract will be awarded for a four-year period. Request for Proposals (RFP) No. NCI-CP-05605-56 will be available on or about November 16, 1989. Proposals will be due 30 days following the actual date of the RFP issuance. The NCI will consider

proposals from all responsible sources. However, offerors must demonstrate in their technical proposal their ability to facilitate delivery of viable tissue and cell specimens to NCI in Bethesda, Maryland, within two hours of collection as a mandatory requirement of the RFP. Failure to demonstrate this element will result in the offeror's elimination from further consideration.

Copies for the RFP may be obtained by sending a written request to:

Donna M. Winters  
Contracting Officer's Representative  
Research Contracts Branch, CECS  
National Cancer Institute  
Executive Plaza South, Room 620  
Bethesda, Maryland 20892

PRESOLICITATION: MULTI-SITE TRIALS OF BEHAVIORAL STRATEGIES  
TO PREVENT THE FURTHER SPREAD OF HIV INFECTION

RFA NUMBERS: MH-89-23, MH-89-24

P.T. 34; K.W. 0715008, 0404000, 0745027, 0755015

National Institute of Mental Health  
National Institute on Drug Abuse  
National Institute on Alcohol Abuse and Alcoholism

INTRODUCTION

The purpose of this announcement is to alert the scientific community to the proposed issuance of two companion Request for Applications (RFAs) for multi-site trials of behavioral strategies to prevent the further spread of HIV infection. Applications will be sought for a Coordinating Center (RFA MH-89-23) and for Extramural Research Groups (RFA MH-89-24).

RESEARCH GOALS AND PHASING

The overall purpose of this program is to support a coordinated research effort, to be undertaken in two phases. Phase one will involve the development and validation of instruments to be used across sites to measure behavioral outcomes in a range of populations at high risk for HIV infection. Pilot studies will be conducted to validate the proposed core battery and to test the behavioral interventions. Phase two will encompass full-scale, cross-site preventive trials with evaluation of the efficacy of the interventions used in reducing high-risk behavior in the populations examined.

MECHANISM OF SUPPORT

The mechanism of support for these RFAs will be the cooperative agreement, an assistance mechanism. Awards made under this mechanism differ from the traditional research grant in that while the awardees are primarily responsible for the conduct of the study, NIMH anticipates substantial involvement in both the planning and coordination of the research.

The responsibilities of the Coordinating Center will include activities such as: organizing meetings required to develop the definitive study plan, training personnel from all sites in common behavioral assessment protocols if required, providing a centralized data base for the study, and coordinating the dissemination of information to the Extramural Research Groups and to the scientific community. The responsibilities of the Extramural Research Groups will include implementing and evaluating the proposed research activities, independently but in a coordinated fashion. Applicants may submit proposals in response to one or both RFAs. Applications submitted in response to either RFA may involve a single institution or a multi-institution collaboration.

Issuance of these RFAs is contingent on administrative approval of the use of the cooperative agreement for this program and on the availability of funds. It is anticipated that approximately \$2 million will be available for this purpose in FY 1990 and that award will be made for a single Coordinating Center and a minimum of two Extramural Research Groups.

Program guidelines and the Request for Applications will be available on or about February 15, 1990. Receipt date for the applications will be June 11, 1990.

## INQUIRIES

For further information or to receive a copy of one or both of the RFAs when available, please send two self-addressed mailing labels to:

Ellen Stover, Ph.D.  
Director, Office of AIDS Programs  
National Institute of Mental Health  
Parklawn Building, Room 17C-04  
5600 Fishers Lane  
Rockville, Maryland 20857  
Telephone: (301) 443-7281

or

Daniela Seminara, Ph.D.  
Deputy Director, Office of AIDS Programs  
National Institute of Mental Health  
Parklawn Building, Room 17C-04  
5600 Fishers Lane  
Rockville, Maryland 20857  
Telephone: (301) 443-7282

## INTERNATIONAL COLLABORATION IN ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH

RFA AVAILABLE: 89-AI-21

P.T. 34; K.W. 0715008, 0785055, 0710030

National Institute of Allergy and Infectious Diseases

Letter of Intent Date: December 15, 1989  
Application Receipt Date: March 30, 1990

The National Institute of Allergy and Infectious Diseases (NIAID) invites applications for the expansion of the International Collaboration in Acquired Immunodeficiency Syndrome (AIDS) Research (ICAR) program to link U.S. institutions to research units in developing countries with significant numbers of persons with HIV infection but which may lack some of the research infrastructure or selected expertise to conduct epidemiological research into HIV infection and disease.

The RFA can be obtained by sending two self-addressed mailing labels to:

Ms. Amy R. Sheon  
Epidemiology Branch  
Division of AIDS  
National Institute of Allergy and Infectious Diseases  
6003 Executive Boulevard  
Bethesda, Maryland 20892  
Telephone: (301) 496-6177

Correspondence sent to Ms. Sheon by overnight or courier service should use Rockville, Maryland 20852 for the city, state, and zip code.

In 1988, five ICARS were awarded to set up collaborative research centers in countries with significant public health problems related to indigenous HIV infection but with some limitations in their research infrastructures, including Brazil, Malawi, Mexico, Uganda, and Zaire. The present initiative would locate 1-2 additional ICARS in developing countries not already participating in the ICAR program where available information suggests that HIV infection is likely to be a major public health problem in the 1990's. The mission of the Division of AIDS (DAIDS) is to find ways to prevent, to treat, and, eventually to cure HIV infection and AIDS. DAIDS has a broad interest in the virology, immunology, pathogenesis, epidemiology, diagnosis, treatment, control and prevention of HIV infection. Of special programmatic interest is perinatal and pediatric infection and heterosexual transmission; variability in HIV isolates in different geographic areas and correlation with clinical and epidemiologic factors; potential role of co-factors; and, similarities and differences in clinical and epidemiologic presentation of disease in different geographical areas.

The ICAR seeks to establish collaborative research initiatives between U.S. and foreign investigators to conduct research on AIDS, a disease of recognized relevance to the health of people in the host countries. It is intended that the effort give priority to the development of self-direction and self-sufficiency of the collaborating foreign laboratory and clinical

investigators. The present initiative will permit a wide range of investigations including, but not limited to the following: a) study of the natural history of HIV infection; (b) identification of risk groups and risk behaviors associated with transmission; (c) establishment of seroprevalence and seroincidence rates among selected populations; (d) evaluation of the immunological parameters that affect susceptibility to infection among the uninfected and infectivity among the infected; (e) assessment of the efficacy of prevention strategies; (f) investigation of the routes of transmission in perinatally acquired infection; and (g) identification of early biological or clinical markers of HIV infection and HIV disease in adult and pediatric cases.

The National Institutes of Health (NIH) and the NIAID place special emphasis on the need for inclusion of individuals belonging to those ethnic groups that are considered to be underrepresented or underprivileged in studies of diseases which disproportionately affect them. Applicants are urged to give special attention, where feasible and appropriate, to the inclusion of these groups in these studies. In addition, the NIH and the NIAID urge the applicants to make a special effort to recruit women into study populations and to devote ICAR resources to studying gender issues related to HIV infection and disease.

Approximately 70-80 percent of the research should be conducted in the foreign country, and the funds should be allocated between the U.S. and host country accordingly. The U.S. grantee institution is responsible for developing a mutually acceptable affiliation with an established university, research institute, federal or state health department, hospital, laboratory, etc., in the host country. For an award to be considered, the domestic applicant institution must include proof of affiliation with a host country institution offering to provide a base for project operations and one or more host country collaborators specified as co-investigators. The grant application will not be reviewed unless proof of an acceptable foreign affiliation is included; a letter of agreement signed by a sanctioned official from the host country institution shall be accepted as proof of affiliation.

Approved grants will be funded for up to five (5) year project-period segments. The total cost per grant should be between \$300,000 and \$500,000 per year for five years (including direct and indirect costs). One (1) to two (2) awards shall be made contingent upon the availability of funds and the receipt of a sufficient number of high quality applications.

Before preparing an application, the prospective applicant should read the NIAID Information Brochure on Program Project and Center Grants, which will be sent along with the RFA, and should carefully follow instructions in the brochure for the preparation of multiproject applications.

SPECIALIZED CENTERS OF RESEARCH IN CHRONIC DISEASES OF THE AIRWAYS, OCCUPATIONAL AND IMMUNOLOGIC LUNG DISEASES, AND LUNG BIOLOGY AND DISEASE IN INFANTS AND CHILDREN

RFA AVAILABLE: 90-HL-01-L

P.T. 04, AA; K.W. 0715165, 0705065, 0785055, 1002004, 1003002, 1002034

National Heart, Lung, and Blood Institute

Application Receipt Date: July 16, 1990

The Division of Lung Diseases of the National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health, announces the availability of a Request for Applications (RFA) for Specialized Centers of Research (SCOR) in Chronic Diseases of the Airways, Occupational and Immunologic Lung Diseases and Lung Biology and Disease in Infants and Children. New applications and applications for renewal of existing centers are invited. Copies of the RFA and Special Instructions for the Preparation of Applications are currently available from NHLBI staff.

The objective of these SCOR programs is to foster multidisciplinary basic and clinical research so that advances in the basic sciences are rapidly translated into effective clinical procedures. Applications are required to contain both basic and clinical research projects. It is anticipated that the results from these SCOR grants will have an impact on the prevention, diagnosis and treatment of the pulmonary diseases addressed in this announcement.

Women and minority individuals should be included in the study population; otherwise, a clear rationale for their exclusion must be provided in the application.

It is anticipated that 14-20 SCORs will be funded.

The requirements and format for applications submitted in response to this announcement and copies of the RFA may be obtained from:

Suzanne S. Hurd, Ph.D.  
Director  
Division of Lung Diseases  
National Heart, Lung, and Blood Diseases  
National Institutes of Health  
Westwood Building, Room 6A16  
Bethesda, Maryland 20892  
Telephone: (301) 496-7208

#### ONGOING PROGRAM ANNOUNCEMENTS

##### PREVENTIVE CARDIOLOGY ACADEMIC AWARD

P.T. 34; K.W. 0785025, 0745027, 0715040

National Heart, Lung, and Blood Institute

Application Receipt Date: April 2, 1990

Each year, the Division of Epidemiology and Clinical Applications (DECA) of the National Heart, Lung, and Blood Institute (NHLBI) invites national competition for Preventive Cardiology Academic Awards (PCAA). These awards have the dual purpose of improving the quality of preventive cardiology curricula and fostering research and careers in the prevention of heart disease.

Previously, any school of medicine or osteopathy in the United States and its possessions or territories was eligible to compete for a PCAA. This year, the eligibility criteria for the PCAA program have been modified. Institutions responding to this announcement should be minority medical schools or medical schools providing physician training to a significant number of underrepresented minorities. Cardiovascular disease is the major cause of death for minorities in the United States, and preventive strategies afford an important opportunity to improve the health status of minorities. Therefore, applicant institutions must demonstrate a commitment and sensitivity to preventive approaches that will address minority health.

For the purposes of the PCAA, the term preventive cardiology is used to define the area of cardiovascular medicine having a special concern with the development and the application of knowledge directed at the prevention of heart and vascular diseases. This includes the primary prevention of cardiovascular diseases in infants, children, and adults who are at risk of developing such diseases and the reduction of preventable complications or disability in persons of all ages who have already developed cardiovascular diseases.

DECA initiated the Preventive Cardiology Academic Award Program to provide a stimulus for development of a preventive cardiology curriculum in those schools that do not have one and to strengthen and improve the preventive cardiology curriculum in those schools that do. Awards provide support to individual faculty members for their educational development and for implementation or expansion of the curriculum in preventive cardiology.

Applications must be received by April 2, 1990, for review at the February, 1991 meeting of the National Heart, Lung, and Blood Advisory Council. Awards will be made with a July 1, 1991 start date. The project period of the PCAA must not exceed five years and each institution may receive the PCAA one time only. The number of new awards will depend on the availability of funds. This is the thirteenth and final announcement for the PCAA program.

The PCAA program is intended to:

- o encourage the development of a high-quality preventive cardiology curriculum in schools of medicine and osteopathy that will significantly increase the opportunities for minority students, house staff, and fellows to learn both the principles and practice of preventive cardiology;

- o develop promising minority faculty whose interest and training are in preventive cardiology teaching, research, and practice;
- o develop established faculty who have a major commitment to and possess educational skills for teaching preventive cardiology;
- o facilitate interchange of educational ideas and methods applicable to teaching preventive cardiology among awardees and institutions; and
- o develop at the grantee institution the ability to strengthen continuously the improved preventive cardiology curriculum, with local funds, subsequent to the award.

Requests for copies of the Preventive Cardiology Academic Award Program Guidelines should be directed to:

Associate Director  
 Clinical Applications and Prevention Program  
 Division of Epidemiology and Clinical Applications  
 National Heart, Lung, and Blood Institute  
 Federal Building, Room 5C-01  
 Bethesda, Maryland 20892  
 Telephone: (301) 496-1706

This program of the NHLBI is identified in the Catalog of Federal Domestic Assistance No. 13.837. Awards will be made under the authority of the Public Health Service Act, Section 301 (42 USC 241) and administered under PHS grant policies and Federal Regulations, most specifically 42 CFR Part 52 and 45 CFR Part 74. This program is not subject to the intergovernmental review requirements of Executive Order 12372 or to Health Systems Agency Review.

RESEARCH TRAINING AND CAREER DEVELOPMENT AWARDS IN DIABETES, ENDOCRINOLOGY, AND METABOLIC DISEASES

P.T. 22, 34; K.W. 0715075, 0715135, 0785050, 1002004, 1002019, 0710070

National Institute of Diabetes and Digestive and Kidney Diseases

BACKGROUND AND SCOPE

The intention of this Program Announcement is to reemphasize the Division of Diabetes, Endocrinology, and Metabolic Diseases' (DDEM) commitment to increasing the number of biomedical investigators who can conduct high quality research in the areas of diabetes, endocrinology, and metabolic diseases. DDEM encourages all individuals, but particularly underrepresented minorities, to submit applications.

Increasingly, problems in diabetes, endocrinology, and metabolism require interdisciplinary approaches. Thus, DDEM wishes to encourage applicants for research training and career development support to develop expertise in areas such as molecular biology, cell biology, immunology, neurology, developmental biology, genetics, and epidemiology as well as in diabetes, endocrinology, and metabolism or metabolic diseases, including cystic fibrosis. This support for professional development may be used to acquire proficiency in sophisticated techniques such as methods for study of protein structure/function, measurement of very low levels of biologically-active molecules, gene transfer techniques, and measurement of ion transport. Applicants seeking to develop such expertise may wish to have mentors in diabetes, endocrinology, or metabolic diseases as well as in another relevant discipline. Suggestions for interdisciplinary training and career development include:

- o Cell biology and endocrinology to investigate the regulation of growth and proliferation of endocrine cells, including the pancreatic islets, and the role of hormones, cytokines, and growth factors in regulation of cell growth in tissues which are under endocrine regulation and in neoplasia;
- o Neurobiology and endocrinology to investigate the role of steroid and peptide hormones in the brain and hormonal involvement in disorders such as stress, depression, and Alzheimer's disease;



- o Developmental biology and endocrinology to study the role of hormones and growth factors in growth and development and cellular differentiation;
- o Immunology and endocrinology to investigate the pathogenesis of autoimmune endocrine disorders including diabetes, Graves' disease, thyroiditis, and Addison's disease;
- o Genetics and diabetes to investigate the genetic basis of Insulin-Dependent and Noninsulin-dependent diabetes;
- o Macromolecular crystallography to study x-ray protein crystal diffraction and apply these techniques to understanding and design of bioactive proteins and enzymes;
- o Computer assisted modeling and molecular dynamics calculations applied to the study of three dimensional protein structure;
- o Biophysical techniques useful in the study of protein structure/function;
- o Wide bore and whole body magnetic resonance spectroscopy and imaging of metabolic processes.

#### MECHANISMS OF SUPPORT

Several mechanisms exist that will support the professional development of individuals who can advance research in these areas. Each mechanism is tailored to a particular stage of the investigator's career. The existing mechanisms are: Individual Fellowship (F32, F33); Physician Scientist Award (PSA) (K11); Clinical Investigator Award (CIA) (K08); and Research Career Development Award (RCDA) (K04).

Physician investigators are encouraged to use the PSA and CIA to develop expertise in basic and clinical research. It is imperative that such a training or career development program equip the physician-investigator to become an independent investigator capable of designing rigorous clinical research protocols carefully crafted to examine a hypothesis. Ideally, such investigators should be able to integrate patient-oriented and laboratory-oriented research methods to address questions related to the physiology and pathophysiology of diabetes, endocrinology, and metabolic diseases, including cystic fibrosis.

The support mechanisms for training and research career development awards are summarized in this announcement. Only citizens and non-citizen nationals are eligible for support under these programs. Detailed guidelines for each of the mechanisms can be obtained from your business office or from the Division of Research Grants, NIH, (301) 496-7441.

#### A. INDIVIDUAL NATIONAL RESEARCH SERVICE AWARD (F32)

Individual National Research Service Awards (NRSA) are given only at the postdoctoral level. The application must describe a specific research project that is guided and sponsored by a preceptor at a particular institution. This support is for full-time research training.

Provisions of NRSA awards include:

Awards up to 36 months of training (waivers may be granted to M.D.s for an additional year);

Stipends based on years of experience: range is \$17,000 - \$31,500;

Institutional allowance of \$3,000 year (\$2,000 for fellows at NIH) to help meet expenses;

Support for more than 12 months requires "payback."

#### B. SENIOR NATIONAL RESEARCH SERVICE AWARD (F33)

Senior fellowships are designed for experienced scientists who wish to make major changes in the direction of their research career, to broaden their research capabilities, or to enlarge their command of an allied research field.

Awards may be for up to 24 months.

Candidates must have received a doctoral degree or equivalent and have had at least 7 subsequent years of relevant professional or research experience.

The stipend is up to \$31,500.

#### APPLICATION SUBMISSION AND REVIEW FOR FELLOWSHIP AWARDS

Application Receipt Dates for these two awards are January 10, May 10, and September 10. Applicants must use Fellowship Application Kit (PHS 416-1, Revised 4/89). Fellowships will be reviewed through the accelerated NIH peer review system in the Division of Research Grants. Funding start dates will be 7 to 8 months after receipt dates.

NOTE: DDEM also supports approximately 41 predoctoral and 220 postdoctoral positions which are administered through Institutional Training Grants (T32s) at over 50 locations throughout the country. For information about applying for these grants or for a list of the currently active Training Grants supported by DDEM, contact the representative listed at the end of this announcement.

#### C. PHYSICIAN SCIENTIST AWARD (K11)

The Physician Scientist Award (PSA) is designed to encourage the newly trained clinician to develop independent research skills and experience in a fundamental science. The award is divided into two phases. During Phase I, which may last 2-3 years, the candidate is expected to develop independent research skills and experience in a fundamental science and may elect to work toward a Ph.D. degree. The primary sponsor must be an accomplished basic science investigator. Phase II entails intensive research activity, applying the skills learned during Phase I.

Applicants for the PSA must:

Hold an M.D. or other health professional degree. Ordinarily candidates holding the Ph.D. are ineligible.

Have completed at least one postgraduate year of clinical training by the time the award is made;

Not have previous independent research support;

Commit at least 75 percent time to PSA activities.

Provisions of the PSA include:

Five years of support, nonrenewable;

Salary up to \$40,000 per year plus fringe benefits;

Up to \$10,000 (Phase I) and \$20,000 (Phase II) per year for research supplies, equipment, technical assistance, travel, etc.;

Up to 10 percent of the primary sponsor's salary and commensurate fringe benefits during the first phase of the award.

Awardees must inform the NIH for each of five years following the completion of the award about academic status, publications, and research grants and contracts received.

#### D. CLINICAL INVESTIGATOR AWARD (K08)

The Clinical Investigator Award (CIA) is offered to provide the opportunity for promising clinically trained individuals with demonstrated aptitude in research to develop into independent investigators. Candidates must have between 4 and 7 years of postdoctoral experience, both clinical and research (a minimum of 2 years of each), by the projected start date.

Applicants for the NIDDK CIA must:

Hold an M.D. or other health professional degree (ordinarily, physicians holding the Ph.D. are ineligible);

Have had approximately 4 to 7 years of postdoctoral experience, clinical and research (a minimum of 2 years of each) by the projected start of the award;

Not have been a principal investigator on a Public Health Service-supported research project.

Provisions of the CIA include:

Five years of support, nonrenewable;

Salary up to \$40,000 per year plus fringe benefits;

Up to \$20,000 per year for research supplies, equipment, technical assistance, travel, etc.;

Commitment of at least 75 percent time to the project.

Awardees must inform the NIH for each of five years following the completion of the award about academic status, publications, and research grants and contracts received.

#### E. RESEARCH CAREER DEVELOPMENT AWARD (K04)

The Research Career Development Award (RCDA) is a special salary grant to enhance the research capabilities of individuals in the formative stages of their careers. Candidates who have demonstrated outstanding potential as independent investigators in health-related research but need to be released from some of the teaching and administrative duties assigned to junior faculty are eligible. The award is not intended for untried investigators or for those already established as independent investigators.

Applicants for the RCDA must:

Hold a doctoral degree or equivalent and have at least 5 years postdoctoral research experience, including 2 years as the principal investigator of a peer-reviewed research grant, prior to the requested beginning date of the award;

Describe in the application how the award will enhance their development as independent investigators;

Have independent research support, funded by the NIDDK, sufficient for the research proposed in the RCDA application;

Hold a faculty appointment.

Provisions of the RCDA include:

Five years of support, nonrenewable;

Salary up to \$40,000 per year plus fringe benefits. No funds are available under this award for research expenses. These expenses are expected to be included in the independent research support described above.

Commitment of at least 80 percent time to research. The remaining time (up to 20 percent) must be spent on research-related activities that will enhance research career development.

RCDA applications may be submitted concurrently with a regular research grant application but may not be submitted concurrently with other development awards such as PSA, CIA, FIRST Award, or Academic Award.

#### APPLICATION SUBMISSION AND REVIEW for the K AWARDS

Application receipt dates for all career development awards (K series) are February 1, June 1, and October 1. The PSA and CIA applications will be reviewed by an NIDDK Review Committee. RCDA applications will be reviewed through the regular NIH peer review system in the Division of Research Grants. Earliest funding dates are approximately 10 months after the receipt dates. Use application form PHS 398, Rev. 10/88, with special instructions for the PSA, CIA, and RCDA ("The K Awards," April 15, 1988).

Applications submitted in response to this announcement should be identified by typing PA-RESEARCH CAREER AWARDS in DDEM on line 2 of the face page, below the title of the project.

For further information about these awards, contact:

Lois F. Lipsett, Ph.D.  
Program Director  
Division of Diabetes, Endocrinology, and Metabolic Diseases  
Westwood Building, Room 620  
Bethesda, Maryland 20892  
Telephone: (301) 496-7433